Rankings
▼
Calendar
CCCC Q3 2025 Earnings — C4 Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
CCCC
C4 Therapeutics, Inc.
$243M
Q3 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$11M
-26.9% YoY
Gross Profit
$11M
100.0% margin
Operating Income
-$34M
-306.4% margin
Net Income
-$32M
-286.4% margin
EPS (Diluted)
$-0.44
QoQ Revenue Growth
+73.8%
Cash Flow
Operating Cash Flow
-$31M
Free Cash Flow
-$32M
Stock-Based Comp.
$5M
Balance Sheet
Total Assets
$265M
Total Liabilities
$111M
Stockholders' Equity
$154M
Cash & Equivalents
$59M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$11M
$15M
-26.9%
Gross Profit
$11M
$13M
-15.6%
Operating Income
-$34M
-$28M
-21.8%
Net Income
-$32M
-$25M
-30.4%
← FY 2025
All Quarters
Q4 2025 →